| Year |
Citation |
Score |
| 2020 |
McClenahan SJ, Gunnell MG, Owens SM, Fantegrossi WE. Active vaccination reduces reinforcing effects of MDPV in male Sprague-Dawley rats trained to self-administer cocaine. Psychopharmacology. PMID 32500210 DOI: 10.1007/S00213-020-05558-0 |
0.626 |
|
| 2020 |
Hay CE, Ewing LE, Hambuchen MD, Zintner SM, Small JC, Bolden CT, Fantegrossi WE, Margaritis P, Owens SM, Peterson EC. The development and characterization of an scFv-Fc fusion based gene therapy to reduce the psychostimulant effects of methamphetamine abuse. The Journal of Pharmacology and Experimental Therapeutics. PMID 32245884 DOI: 10.1124/Jpet.119.261180 |
0.788 |
|
| 2019 |
Keller CM, Spence AL, Stevens MW, Owens SM, Guerin GF, Goeders NE. Effects of a methamphetamine vaccine, IXT-v100, on methamphetamine-related behaviors. Psychopharmacology. PMID 31758209 DOI: 10.1007/S00213-019-05399-6 |
0.336 |
|
| 2019 |
McClenahan SJ, Kormos CM, Gunnell M, Hambuchen MD, Lamb P, Carroll FI, Lewin AH, Peterson EC, Owens SM. Design, synthesis and biological evaluation of a bi-specific vaccine against α-pyrrolidinovalerophenone (α-PVP) and 3,4-methylenedioxypyrovalerone (MDPV) in rats. Vaccine. PMID 31629568 DOI: 10.1016/J.Vaccine.2019.10.008 |
0.735 |
|
| 2019 |
Stevens MW, Rüedi-Bettschen D, Gunnell MG, Tawney R, West CM, Owens SM. Antibody production and pharmacokinetics of METH in rats following vaccination with the METH vaccine, IXT-v100, adjuvanted with GLA-SE. Drug and Alcohol Dependence. 204: 107484. PMID 31521953 DOI: 10.1016/J.Drugalcdep.2019.05.016 |
0.389 |
|
| 2019 |
Hambuchen MD, Berquist MD, Simecka CM, McGill MR, Gunnell MG, Hendrickson HP, Owens SM. Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats. Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society For Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques. 22: 301-312. PMID 31329536 DOI: 10.18433/Jpps30471 |
0.702 |
|
| 2019 |
Griffin BA, Caperton CO, Russell LN, Cabalong CV, Wilson CD, Urquhart KR, Martins BS, Zita MD, Patton AL, Alund AW, Owens SM, Fantegrossi WE, Moran JH, Brents LK. exposure to norbuprenorphine, a major metabolite of buprenorphine, induces fetal opioid dependence and leads to neonatal opioid withdrawal syndrome. The Journal of Pharmacology and Experimental Therapeutics. PMID 31028107 DOI: 10.1124/Jpet.118.254219 |
0.635 |
|
| 2019 |
McClenahan SJ, Hambuchen MD, Simecka CM, Gunnell MG, Berquist MD, Owens SM. Cardiovascular effects of 3,4-methylenedioxypyrovalerone (MDPV) in male and female Sprague-Dawley rats. Drug and Alcohol Dependence. 195: 140-147. PMID 30634109 DOI: 10.1016/J.Drugalcdep.2018.12.006 |
0.726 |
|
| 2018 |
Hay CE, Gonzalez GA, Ewing LE, Reichard EE, Hambuchen MD, Nanaware-Kharade N, Alam S, Bolden CT, Owens SM, Margaritis P, Peterson EC. Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse. Plos One. 13: e0200060. PMID 29958300 DOI: 10.1371/Journal.Pone.0200060 |
0.755 |
|
| 2017 |
Hambuchen MD, Hendrickson HP, Gunnell MG, McClenahan SJ, Ewing LE, Gibson DM, Berquist MD, Owens SM. The pharmacokinetics of racemic MDPV and its (R) and (S) enantiomers in female and male rats. Drug and Alcohol Dependence. 179: 347-354. PMID 28844011 DOI: 10.1016/J.Drugalcdep.2017.07.011 |
0.707 |
|
| 2017 |
Hambuchen MD, Hendrickson HP, Owens SM. Chiral determination of 3,4-methylenedioxypyrovalerone enantiomers in rat serum. Analytical Methods : Advancing Methods and Applications. 9: 609-617. PMID 28286575 DOI: 10.1039/C6Ay03176E |
0.712 |
|
| 2016 |
Owens SM, Pollard GT, Howard JL, Fennell TR, Snyder RW, Carroll FI. Pharmacodynamic Relationships between Duration of Action of JDTic-like Kappa-Opioid Receptor Antagonists and Their Brain and Plasma Pharmacokinetics in Rats. Acs Chemical Neuroscience. PMID 27700049 DOI: 10.1021/Acschemneuro.6B00249 |
0.307 |
|
| 2016 |
Reichard EE, Nanaware-Kharade N, Gonzalez GA, Thakkar S, Owens SM, Peterson EC. PEGylation of a High-Affinity Anti-(+)Methamphetamine Single Chain Antibody Fragment Extends Functional Half-Life by Reducing Clearance. Pharmaceutical Research. PMID 27620175 DOI: 10.1007/S11095-016-2017-Y |
0.423 |
|
| 2016 |
Hambuchen MD, Rüedi-Bettschen D, Gunnell MG, Hendrickson H, Owens SM. Chronic Treatment of (+)-Methamphetamine-Induced Locomotor Effects in Rats Using One or a Combination of Two High Affinity Anti-Methamphetamine Monoclonal Antibodies. Human Vaccines & Immunotherapeutics. 0. PMID 27163775 DOI: 10.1080/21645515.2016.1179407 |
0.784 |
|
| 2016 |
Stevens MW, Gunnell MG, Tawney R, Owens SM. Optimization of a methamphetamine conjugate vaccine for antibody production in mice. International Immunopharmacology. 35: 137-141. PMID 27039212 DOI: 10.1016/J.Intimp.2016.03.028 |
0.406 |
|
| 2015 |
Harris AC, LeSage MG, Shelley D, Perry JL, Pentel PR, Owens SM. Correction: The Anti-(+)-Methamphetamine Monoclonal Antibody mAb7F9 Attenuates Acute (+)-Methamphetamine Effects on Intracranial Self-Stimulation in Rats. Plos One. 10: e0138959. PMID 26383646 DOI: 10.1371/journal.pone.0138959 |
0.343 |
|
| 2015 |
Hambuchen MD, Carroll FI, Rüedi-Bettschen D, Hendrickson HP, Hennings LJ, Blough BE, Brieaddy LE, Pidaparthi RR, Owens SM. Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response. Journal of Medicinal Chemistry. 58: 4665-77. PMID 25973614 DOI: 10.1021/Acs.Jmedchem.5B00220 |
0.762 |
|
| 2015 |
Harris AC, LeSage MG, Shelley D, Perry JL, Pentel PR, Owens SM. The anti-(+)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)-methamphetamine effects on intracranial self-stimulation in rats. Plos One. 10: e0118787. PMID 25742165 DOI: 10.1371/Journal.Pone.0118787 |
0.458 |
|
| 2014 |
Stevens MW, Henry RL, Owens SM, Schutz R, Gentry WB. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers. Mabs. 6: 1649-56. PMID 25484042 DOI: 10.4161/19420862.2014.976431 |
0.393 |
|
| 2014 |
Laurenzana EM, Stevens MW, Frank JC, Hambuchen MD, Hendrickson HP, White SJ, Williams DK, Owens SM, Gentry WB. Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development. Human Vaccines & Immunotherapeutics. 10: 2638-47. PMID 25483484 DOI: 10.4161/Hv.29707 |
0.776 |
|
| 2014 |
Peterson EC, Hambuchen MD, Tawney RL, Gunnell MG, Cowell JL, Lay JO, Blough BE, Carroll FI, Owens SM. Simple radiometric method for accurately quantitating epitope densities of hapten-protein conjugates with sulfhydryl linkages. Bioconjugate Chemistry. 25: 2112-5. PMID 25426820 DOI: 10.1021/bc500456z |
0.683 |
|
| 2014 |
Hambuchen MD, Rüedi-Bettschen D, Williams DK, Hendrickson H, Owens SM. Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period. Vaccine. 32: 6213-9. PMID 25252196 DOI: 10.1016/J.Vaccine.2014.09.025 |
0.781 |
|
| 2014 |
White SJ, Hendrickson HP, Atchley WT, Laurenzana EM, Gentry WB, Williams DK, Owens SM. Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 1285-91. PMID 24839971 DOI: 10.1124/Dmd.114.056879 |
0.483 |
|
| 2014 |
Peterson EC, Gentry WB, Owens SM. Customizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applications. Advances in Pharmacology (San Diego, Calif.). 69: 107-27. PMID 24484976 DOI: 10.1016/B978-0-12-420118-7.00003-2 |
0.434 |
|
| 2013 |
Rüedi-Bettschen D, Wood SL, Gunnell MG, West CM, Pidaparthi RR, Carroll FI, Blough BE, Owens SM. Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food. Vaccine. 31: 4596-602. PMID 23906885 DOI: 10.1016/J.Vaccine.2013.07.038 |
0.432 |
|
| 2011 |
Owens SM, Atchley WT, Hambuchen MD, Peterson EC, Gentry WB. Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction. Cns & Neurological Disorders Drug Targets. 10: 892-8. PMID 22229314 DOI: 10.2174/187152711799219370 |
0.761 |
|
| 2011 |
Hubbard JJ, Laurenzana EM, Williams DK, Gentry WB, Owens SM. Chronic anti-phencyclidine monoclonal antibody therapy decreases phencyclidine-induced in utero fetal mortality in pregnant rats. International Immunopharmacology. 11: 2181-7. PMID 22001428 DOI: 10.1016/J.Intimp.2011.09.016 |
0.765 |
|
| 2011 |
White S, Laurenzana E, Hendrickson H, Gentry WB, Owens SM. Gestation time-dependent pharmacokinetics of intravenous (+)-methamphetamine in rats. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 1718-26. PMID 21632964 DOI: 10.1124/Dmd.111.039446 |
0.419 |
|
| 2011 |
Hubbard JJ, Laurenzana EM, Williams DK, Gentry WB, Owens SM. The fate and function of therapeutic antiaddiction monoclonal antibodies across the reproductive cycle of rats. The Journal of Pharmacology and Experimental Therapeutics. 336: 414-22. PMID 20962030 DOI: 10.1124/Jpet.110.175083 |
0.772 |
|
| 2010 |
Gentry WB, Rüedi-Bettschen D, Owens SM. Anti-(+)-methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction. Clinical Pharmacology and Therapeutics. 88: 390-3. PMID 20668443 DOI: 10.1038/clpt.2010.155 |
0.327 |
|
| 2009 |
Carroll FI, Abraham P, Gong PK, Pidaparthi RR, Blough BE, Che Y, Hampton A, Gunnell M, Lay JO, Peterson EC, Owens SM. The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse. Journal of Medicinal Chemistry. 52: 7301-9. PMID 19877685 DOI: 10.1021/Jm901134W |
0.384 |
|
| 2009 |
Laurenzana EM, Hendrickson HP, Carpenter D, Peterson EC, Gentry WB, West M, Che Y, Carroll FI, Owens SM. Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats. Vaccine. 27: 7011-20. PMID 19800446 DOI: 10.1016/J.Vaccine.2009.09.072 |
0.504 |
|
| 2009 |
Celikel R, Peterson EC, Owens SM, Varughese KI. Crystal structures of a therapeutic single chain antibody in complex with two drugs of abuse-Methamphetamine and 3,4-methylenedioxymethamphetamine. Protein Science : a Publication of the Protein Society. 18: 2336-45. PMID 19760665 DOI: 10.1002/Pro.244 |
0.395 |
|
| 2009 |
Peterson EC, Owens SM. Designing immunotherapies to thwart drug abuse. Molecular Interventions. 9: 119-24. PMID 19592672 DOI: 10.1124/Mi.9.3.5 |
0.41 |
|
| 2009 |
White SJ, Laurenzana EM, Gentry WB, Hendrickson HP, Williams DK, Ward KW, Owens SM. Vulnerability to (+)-methamphetamine effects and the relationship to drug disposition in pregnant rats during chronic infusion. Toxicological Sciences : An Official Journal of the Society of Toxicology. 111: 27-36. PMID 19520673 DOI: 10.1093/toxsci/kfp127 |
0.331 |
|
| 2009 |
Gentry WB, Rüedi-Bettschen D, Owens SM. Development of active and passive human vaccines to treat methamphetamine addiction. Human Vaccines. 5: 206-13. PMID 19276653 DOI: 10.4161/Hv.5.4.7456 |
0.441 |
|
| 2008 |
Hendrickson HP, Hardwick WC, McMillan DE, Owens SM. Bioavailability of (+)-methamphetamine in the pigeon following an intramuscular dose. Pharmacology, Biochemistry, and Behavior. 90: 382-6. PMID 18455783 DOI: 10.1016/J.Pbb.2008.03.012 |
0.36 |
|
| 2008 |
Peterson EC, Laurenzana EM, Atchley WT, Hendrickson HP, Owens SM. Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine. The Journal of Pharmacology and Experimental Therapeutics. 325: 124-33. PMID 18192498 DOI: 10.1124/Jpet.107.134395 |
0.479 |
|
| 2008 |
Lacy HM, Gunnell MG, Laurenzana EM, Owens SM. Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody. International Immunopharmacology. 8: 1-11. PMID 18068094 DOI: 10.1016/J.Intimp.2007.09.020 |
0.337 |
|
| 2008 |
Naef L, Srivastava L, Gratton A, Hendrickson H, Owens SM, Walker CD. Maternal high fat diet during the perinatal period alters mesocorticolimbic dopamine in the adult rat offspring: reduction in the behavioral responses to repeated amphetamine administration. Psychopharmacology. 197: 83-94. PMID 18004547 DOI: 10.1007/S00213-007-1008-4 |
0.304 |
|
| 2007 |
Peterson EC, Gunnell M, Che Y, Goforth RL, Carroll FI, Henry R, Liu H, Owens SM. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. The Journal of Pharmacology and Experimental Therapeutics. 322: 30-9. PMID 17452421 DOI: 10.1124/Jpet.106.117150 |
0.447 |
|
| 2007 |
Milesi-Hallé A, McMillan DE, Laurenzana EM, Byrnes-Blake KA, Owens SM. Sex differences in (+)-amphetamine- and (+)-methamphetamine-induced behavioral response in male and female Sprague-Dawley rats. Pharmacology, Biochemistry, and Behavior. 86: 140-9. PMID 17275894 DOI: 10.1016/J.Pbb.2006.12.018 |
0.751 |
|
| 2006 |
Hendrickson H, Laurenzana E, Owens SM. Quantitative determination of total methamphetamine and active metabolites in rat tissue by liquid chromatography with tandem mass spectrometric detection. The Aaps Journal. 8: E709-17. PMID 17233534 DOI: 10.1208/Aapsj080480 |
0.309 |
|
| 2006 |
Peterson E, Owens SM, Henry RL. Monoclonal antibody form and function: manufacturing the right antibodies for treating drug abuse. The Aaps Journal. 8: E383-90. PMID 16796389 DOI: 10.1007/Bf02854909 |
0.452 |
|
| 2006 |
Gentry WB, Laurenzana EM, Williams DK, West JR, Berg RJ, Terlea T, Owens SM. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. International Immunopharmacology. 6: 968-77. PMID 16644483 DOI: 10.1016/J.Intimp.2006.01.008 |
0.536 |
|
| 2006 |
Pitas G, Laurenzana EM, Williams DK, Owens SM, Gentry WB. Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 906-12. PMID 16507651 DOI: 10.1124/Dmd.105.005934 |
0.547 |
|
| 2006 |
Daniels JR, Wessinger WD, Hardwick WC, Li M, Gunnell MG, Hall CJ, Owens SM, McMillan DE. Effects of anti-phencyclidine and anti-(+)-methamphetamine monoclonal antibodies alone and in combination on the discrimination of phencyclidine and (+)-methamphetamine by pigeons. Psychopharmacology. 185: 36-44. PMID 16479372 DOI: 10.1007/s00213-005-0299-6 |
0.395 |
|
| 2005 |
Byrnes-Blake KA, Laurenzana EM, Landes RD, Gentry WB, Owens SM. Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats. European Journal of Pharmacology. 521: 86-94. PMID 16182279 DOI: 10.1016/J.Ejphar.2005.08.016 |
0.789 |
|
| 2005 |
Kosten T, Owens SM. Immunotherapy for the treatment of drug abuse. Pharmacology & Therapeutics. 108: 76-85. PMID 16023218 DOI: 10.1016/J.Pharmthera.2005.06.009 |
0.456 |
|
| 2005 |
Milesi-Hallé A, Hendrickson HP, Laurenzana EM, Gentry WB, Owens SM. Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats. Toxicology and Applied Pharmacology. 209: 203-13. PMID 15916788 DOI: 10.1016/J.Taap.2005.04.007 |
0.433 |
|
| 2004 |
Gentry WB, Ghafoor AU, Wessinger WD, Laurenzana EM, Hendrickson HP, Owens SM. (+)-Methamphetamine-induced spontaneous behavior in rats depends on route of (+)METH administration. Pharmacology, Biochemistry, and Behavior. 79: 751-60. PMID 15582684 DOI: 10.1016/J.Pbb.2004.10.006 |
0.438 |
|
| 2004 |
McMillan DE, Hardwick WC, Li M, Gunnell MG, Carroll FI, Abraham P, Owens SM. Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. The Journal of Pharmacology and Experimental Therapeutics. 309: 1248-55. PMID 14993256 DOI: 10.1124/jpet.103.061762 |
0.385 |
|
| 2004 |
Owens SM. Monoclonal antibodies as drugs Drug Development Research. 61: 107. DOI: 10.1002/Ddr.10350 |
0.407 |
|
| 2003 |
Laurenzana EM, Byrnes-Blake KA, Milesi-Hallé A, Gentry WB, Williams DK, Owens SM. Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 31: 1320-6. PMID 14570763 DOI: 10.1124/Dmd.31.11.1320 |
0.793 |
|
| 2003 |
Laurenzana EM, Gunnell MG, Gentry WB, Owens SM. Treatment of adverse effects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody. The Journal of Pharmacology and Experimental Therapeutics. 306: 1092-8. PMID 12829731 DOI: 10.1124/Jpet.103.053140 |
0.472 |
|
| 2003 |
Byrnes-Blake KA, Laurenzana EM, Carroll FI, Abraham P, Gentry WB, Landes RD, Owens SM. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. European Journal of Pharmacology. 461: 119-28. PMID 12586207 DOI: 10.1016/S0014-2999(03)01313-X |
0.797 |
|
| 2002 |
McMillan DE, Hardwick WC, Li M, Owens SM. Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody. Behavioural Pharmacology. 13: 465-73. PMID 12394422 |
0.369 |
|
| 2002 |
Hardin JS, Wessinger WD, Wenger GR, Proksch JW, Laurenzana EM, Owens SM. A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats. The Journal of Pharmacology and Experimental Therapeutics. 302: 119-26. PMID 12065708 DOI: 10.1124/Jpet.302.1.119 |
0.548 |
|
| 2001 |
Arora H, Owens SM, Gentry WB. Intravenous (+)-methamphetamine causes complex dose-dependent physiologic changes in awake rats. European Journal of Pharmacology. 426: 81-7. PMID 11525775 DOI: 10.1016/S0014-2999(01)01202-X |
0.392 |
|
| 2001 |
Byrnes-Blake KA, Carroll FI, Abraham P, Owens SM. Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. International Immunopharmacology. 1: 329-38. PMID 11360933 DOI: 10.1016/S1567-5769(00)00019-9 |
0.774 |
|
| 2001 |
Kyosseva SV, Owens SM, Elbein AD, Karson CN. Differential and region-specific activation of mitogen-activated protein kinases following chronic administration of phencyclidine in rat brain Neuropsychopharmacology. 24: 267-277. PMID 11166517 DOI: 10.1016/S0893-133X(00)00180-9 |
0.36 |
|
| 2000 |
Proksch JW, Gentry WB, Owens SM. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. The Journal of Pharmacology and Experimental Therapeutics. 292: 831-7. PMID 10688594 |
0.421 |
|
| 1998 |
Proksch JW, Gentry WB, Owens SM. Pharmacokinetic mechanisms for obtaining high renal coelimination of phencyclidine and a monoclonal antiphencyclidine antigen-binding fragment of immunoglobulin G in the rat. The Journal of Pharmacology and Experimental Therapeutics. 287: 616-24. PMID 9808688 |
0.338 |
|
| 1998 |
Hardin JS, Wessinger WD, Proksch JW, Owens SM. Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs. The Journal of Pharmacology and Experimental Therapeutics. 285: 1113-22. PMID 9618414 |
0.365 |
|
| 1997 |
Laurenzana EM, Owens SM. Brain microsomal metabolism of phencyclidine in male and female rats Brain Research. 756: 256-265. PMID 9187340 DOI: 10.1016/S0006-8993(97)00203-5 |
0.363 |
|
| 1996 |
Valentine JL, Owens SM. Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats Journal of Pharmacology and Experimental Therapeutics. 278: 717-724. PMID 8768723 |
0.378 |
|
| 1996 |
Valentine JL, Mayersohn M, Wessinger WD, Arnold LW, Owens SM. Antiphencyclidine monoclonal Fab fragments reverse phencyclidine- induced behavioral effects and ataxia in rats Journal of Pharmacology and Experimental Therapeutics. 278: 709-716. PMID 8768722 |
0.378 |
|
| 1996 |
Shelnutt SR, Badger TM, Owens SM. Phencyclidine metabolite irreversible binding in the rat: Gonadal steroid regulation and CYP2C11 Journal of Pharmacology and Experimental Therapeutics. 277: 292-298. PMID 8613933 |
0.301 |
|
| 1994 |
Valentine JL, Arnold LW, Owens SM. Anti-phencyclidine monoclonal Fab fragments markedly alter phencyclidine pharmacokinetics in rats Journal of Pharmacology and Experimental Therapeutics. 269: 1079-1085. PMID 8014850 |
0.3 |
|
| 1993 |
Owens SM, Gunnell M, Laurenzana EM, Valentine JL. Dose- and time-dependent changes in phencyclidine metabolite covalent binding in rats and the possible role of CYP2D1 Journal of Pharmacology and Experimental Therapeutics. 265: 1261-1266. PMID 8510006 |
0.301 |
|
| 1993 |
McClurkan MB, Valentine JL, Arnold L, Owens SM. Disposition of a monoclonal anti-phencyclidine Fab fragment of immunoglobulin G in rats Journal of Pharmacology and Experimental Therapeutics. 266: 1439-1445. PMID 8371148 |
0.329 |
|
| 1990 |
Owens SM, McMillan DE, Hardwick WC, Wessinger WD. Phencyclidine pharmacokinetics and concentration-response relationships in the pigeon. Pharmacology, Biochemistry, and Behavior. 35: 797-801. PMID 2345758 DOI: 10.1016/0091-3057(90)90361-K |
0.346 |
|
| 1990 |
Evans RL, Owens SM, Ruch S, Kennedy RH, Seifen E. The effect of age on digoxin pharmacokinetics in Fischer-344 rats Toxicology and Applied Pharmacology. 102: 61-67. PMID 2296772 DOI: 10.1016/0041-008X(90)90083-7 |
0.348 |
|
| 1986 |
Owens SM, Mayersohn M. Modulation of phencyclidine (PCP) pharmacokinetics with PCP-specific fab fragments Nida Research Monograph Series. 112-126. PMID 3086729 |
0.303 |
|
| 1986 |
Owens SM, Mayersohn M. Phencyclidine-specific Fab fragments alter phencyclidine disposition in dogs Drug Metabolism and Disposition. 14: 52-58. PMID 2868866 |
0.322 |
|
| Show low-probability matches. |